APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Factor VIII Concentrate

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Factor VIII Concentrate Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchHuman Factor VIII Concentrate Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Factor VIII Concentrate Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Human Factor VIII Concentrate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Factor VIII Concentrate Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Factor VIII Concentrate Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Factor VIII Concentrate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Factor VIII Concentrate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Factor VIII Concentrate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Factor VIII Concentrate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Factor VIII Concentrate market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Factor VIII Concentrate market include Shandong Taibang Biological Products, Shanghai Xinxing Medicine, Shanghai Raas Corp, Novo Nordisk A/S, Grifols, Pfizer, Hualan Biological, Bayer and SinoCell Tech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Factor VIII Concentrate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Factor VIII Concentrate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Factor VIII Concentrate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Factor VIII Concentrate market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Factor VIII Concentrate Segment by Company

Shandong Taibang Biological Products

Shanghai Xinxing Medicine

Shanghai Raas Corp

Novo Nordisk A/S

Grifols

Pfizer

Hualan Biological

Bayer

SinoCell Tech

Shire (Baxter)

Octapharma

NovoNordisk

GC Pharma

CSL

Biogen

Human Factor VIII Concentrate Segment by Type

Blood Extraction

Recombine

Human Factor VIII Concentrate Segment by Application

Von Willebrand's Disease

Congenital Coagulation Factor VIII Deficiency

Acquired Factor VIII Deficiency

Human Factor VIII Concentrate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Factor VIII Concentrate status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Factor VIII Concentrate market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Factor VIII Concentrate significant trends, drivers, influence factors in global and regions.

6. To analyze Human Factor VIII Concentrate competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Factor VIII Concentrate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Factor VIII Concentrate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Factor VIII Concentrate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Factor VIII Concentrate market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Factor VIII Concentrate industry.

Chapter 3: Detailed analysis of Human Factor VIII Concentrate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Factor VIII Concentrate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Factor VIII Concentrate in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Factor VIII Concentrate Industry Trends Table 2. Human Factor VIII Concentrate Industry Drivers Table 3. Human Factor VIII Concentrate Industry Opportunities and Challenges Table 4. Human Factor VIII Concentrate Industry Restraints Table 5. Global Human Factor VIII Concentrate Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Factor VIII Concentrate Revenue Share by Company (2021-2026) Table 7. Global Human Factor VIII Concentrate Sales Volume by Company (k units) & (2021-2026) Table 8. Global Human Factor VIII Concentrate Sales Volume Share by Company (2021-2026) Table 9. Global Human Factor VIII Concentrate Average Price (US$/unit) of Company (2021-2026) Table 10. Global Human Factor VIII Concentrate Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Factor VIII Concentrate Key Company Manufacturing Base & Headquarters Table 12. Global Human Factor VIII Concentrate Company, Product Type & Application Table 13. Global Human Factor VIII Concentrate Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Factor VIII Concentrate by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Blood Extraction Table 18. Significant Companies of Recombine Table 19. Global Human Factor VIII Concentrate Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Human Factor VIII Concentrate Sales Volume by Type (2021-2026) & (k units) Table 21. Global Human Factor VIII Concentrate Sales Volume by Type (2027-2032) & (k units) Table 22. Global Human Factor VIII Concentrate Sales Volume Share by Type (2021-2026) Table 23. Global Human Factor VIII Concentrate Sales Volume Share by Type (2027-2032) Table 24. Global Human Factor VIII Concentrate Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Factor VIII Concentrate Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Human Factor VIII Concentrate Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Human Factor VIII Concentrate Sales Value Share by Type (2021-2026) Table 28. Global Human Factor VIII Concentrate Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Von Willebrand's Disease Table 30. Significant Companies of Congenital Coagulation Factor VIII Deficiency Table 31. Significant Companies of Acquired Factor VIII Deficiency Table 32. Global Human Factor VIII Concentrate Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Human Factor VIII Concentrate Sales Volume by Application (2021-2026) & (k units) Table 34. Global Human Factor VIII Concentrate Sales Volume by Application (2027-2032) & (k units) Table 35. Global Human Factor VIII Concentrate Sales Volume Share by Application (2021-2026) Table 36. Global Human Factor VIII Concentrate Sales Volume Share by Application (2027-2032) Table 37. Global Human Factor VIII Concentrate Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Human Factor VIII Concentrate Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Human Factor VIII Concentrate Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Human Factor VIII Concentrate Sales Value Share by Application (2021-2026) Table 41. Global Human Factor VIII Concentrate Sales Value Share by Application (2027-2032) Table 42. Global Human Factor VIII Concentrate Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Human Factor VIII Concentrate Sales by Region (2021-2026) & (k units) Table 44. Global Human Factor VIII Concentrate Sales Market Share by Region (2021-2026) Table 45. Global Human Factor VIII Concentrate Sales by Region (2027-2032) & (k units) Table 46. Global Human Factor VIII Concentrate Sales Market Share by Region (2027-2032) Table 47. Global Human Factor VIII Concentrate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Human Factor VIII Concentrate Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Human Factor VIII Concentrate Sales Value Share by Region (2021-2026) Table 50. Global Human Factor VIII Concentrate Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Human Factor VIII Concentrate Sales Value Share by Region (2027-2032) Table 52. Global Human Factor VIII Concentrate Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Human Factor VIII Concentrate Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Human Factor VIII Concentrate Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Human Factor VIII Concentrate Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Human Factor VIII Concentrate Sales by Country (2021-2026) & (k units) Table 57. Global Human Factor VIII Concentrate Sales Market Share by Country (2021-2026) Table 58. Global Human Factor VIII Concentrate Sales by Country (2027-2032) & (k units) Table 59. Global Human Factor VIII Concentrate Sales Market Share by Country (2027-2032) Table 60. Global Human Factor VIII Concentrate Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Human Factor VIII Concentrate Sales Value Market Share by Country (2021-2026) Table 62. Global Human Factor VIII Concentrate Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Human Factor VIII Concentrate Sales Value Market Share by Country (2027-2032) Table 64. Shandong Taibang Biological Products Company Information Table 65. Shandong Taibang Biological Products Business Overview Table 66. Shandong Taibang Biological Products Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Shandong Taibang Biological Products Human Factor VIII Concentrate Product Portfolio Table 68. Shandong Taibang Biological Products Recent Development Table 69. Shanghai Xinxing Medicine Company Information Table 70. Shanghai Xinxing Medicine Business Overview Table 71. Shanghai Xinxing Medicine Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Shanghai Xinxing Medicine Human Factor VIII Concentrate Product Portfolio Table 73. Shanghai Xinxing Medicine Recent Development Table 74. Shanghai Raas Corp Company Information Table 75. Shanghai Raas Corp Business Overview Table 76. Shanghai Raas Corp Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Shanghai Raas Corp Human Factor VIII Concentrate Product Portfolio Table 78. Shanghai Raas Corp Recent Development Table 79. Novo Nordisk A/S Company Information Table 80. Novo Nordisk A/S Business Overview Table 81. Novo Nordisk A/S Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Novo Nordisk A/S Human Factor VIII Concentrate Product Portfolio Table 83. Novo Nordisk A/S Recent Development Table 84. Grifols Company Information Table 85. Grifols Business Overview Table 86. Grifols Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Grifols Human Factor VIII Concentrate Product Portfolio Table 88. Grifols Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Pfizer Human Factor VIII Concentrate Product Portfolio Table 93. Pfizer Recent Development Table 94. Hualan Biological Company Information Table 95. Hualan Biological Business Overview Table 96. Hualan Biological Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Hualan Biological Human Factor VIII Concentrate Product Portfolio Table 98. Hualan Biological Recent Development Table 99. Bayer Company Information Table 100. Bayer Business Overview Table 101. Bayer Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Bayer Human Factor VIII Concentrate Product Portfolio Table 103. Bayer Recent Development Table 104. SinoCell Tech Company Information Table 105. SinoCell Tech Business Overview Table 106. SinoCell Tech Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. SinoCell Tech Human Factor VIII Concentrate Product Portfolio Table 108. SinoCell Tech Recent Development Table 109. Shire (Baxter) Company Information Table 110. Shire (Baxter) Business Overview Table 111. Shire (Baxter) Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Shire (Baxter) Human Factor VIII Concentrate Product Portfolio Table 113. Shire (Baxter) Recent Development Table 114. Octapharma Company Information Table 115. Octapharma Business Overview Table 116. Octapharma Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Octapharma Human Factor VIII Concentrate Product Portfolio Table 118. Octapharma Recent Development Table 119. NovoNordisk Company Information Table 120. NovoNordisk Business Overview Table 121. NovoNordisk Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. NovoNordisk Human Factor VIII Concentrate Product Portfolio Table 123. NovoNordisk Recent Development Table 124. GC Pharma Company Information Table 125. GC Pharma Business Overview Table 126. GC Pharma Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. GC Pharma Human Factor VIII Concentrate Product Portfolio Table 128. GC Pharma Recent Development Table 129. CSL Company Information Table 130. CSL Business Overview Table 131. CSL Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. CSL Human Factor VIII Concentrate Product Portfolio Table 133. CSL Recent Development Table 134. Biogen Company Information Table 135. Biogen Business Overview Table 136. Biogen Human Factor VIII Concentrate Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Biogen Human Factor VIII Concentrate Product Portfolio Table 138. Biogen Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Human Factor VIII Concentrate Distributors List Table 142. Human Factor VIII Concentrate Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Human Factor VIII Concentrate Product Image Figure 2. Global Human Factor VIII Concentrate Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Factor VIII Concentrate Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Factor VIII Concentrate Sales (2021-2032) & (k units) Figure 5. Global Human Factor VIII Concentrate Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Human Factor VIII Concentrate Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Blood Extraction Image Figure 10. Recombine Image Figure 11. Global Human Factor VIII Concentrate Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Human Factor VIII Concentrate Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Human Factor VIII Concentrate Sales Volume Share by Type (2021-2032) Figure 14. Global Human Factor VIII Concentrate Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Factor VIII Concentrate Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Factor VIII Concentrate Sales Value Share by Type (2021-2032) Figure 17. Von Willebrand's Disease Image Figure 18. Congenital Coagulation Factor VIII Deficiency Image Figure 19. Acquired Factor VIII Deficiency Image Figure 20. Global Human Factor VIII Concentrate Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Human Factor VIII Concentrate Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Human Factor VIII Concentrate Sales Volume Share by Application (2021-2032) Figure 23. Global Human Factor VIII Concentrate Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Human Factor VIII Concentrate Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Human Factor VIII Concentrate Sales Value Share by Application (2021-2032) Figure 26. Global Human Factor VIII Concentrate Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Human Factor VIII Concentrate Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Human Factor VIII Concentrate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Human Factor VIII Concentrate Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Human Factor VIII Concentrate Sales Value (2021-2032) & (US$ Million) Figure 31. North America Human Factor VIII Concentrate Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Human Factor VIII Concentrate Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Human Factor VIII Concentrate Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Human Factor VIII Concentrate Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Human Factor VIII Concentrate Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Human Factor VIII Concentrate Sales Value (2021-2032) & (US$ Million) Figure 37. South America Human Factor VIII Concentrate Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Human Factor VIII Concentrate Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Human Factor VIII Concentrate Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Human Factor VIII Concentrate Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Human Factor VIII Concentrate Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Extraction
  • Recombine
Applications
  • Von Willebrand's Disease
  • Congenital Coagulation Factor VIII Deficiency
  • Acquired Factor VIII Deficiency
Companies covered
  • Shandong Taibang Biological Products
  • Shanghai Xinxing Medicine
  • Shanghai Raas Corp
  • Novo Nordisk A/S
  • Grifols
  • Pfizer
  • Hualan Biological
  • Bayer
  • SinoCell Tech
  • Shire (Baxter)
  • Octapharma
  • NovoNordisk
  • GC Pharma
  • CSL
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Factor VIII Concentrate Sales Value (2021-2032)
  4. 1.2.2 Global Human Factor VIII Concentrate Sales Volume (2021-2032)
  5. 1.2.3 Global Human Factor VIII Concentrate Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Factor VIII Concentrate Market Dynamics
  1. 2.1 Human Factor VIII Concentrate Industry Trends
  2. 2.2 Human Factor VIII Concentrate Industry Drivers
  3. 2.3 Human Factor VIII Concentrate Industry Opportunities and Challenges
  4. 2.4 Human Factor VIII Concentrate Industry Restraints
3 Human Factor VIII Concentrate Market by Company
  1. 3.1 Global Human Factor VIII Concentrate Company Revenue Ranking in 2025
  2. 3.2 Global Human Factor VIII Concentrate Revenue by Company (2021-2026)
  3. 3.3 Global Human Factor VIII Concentrate Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Factor VIII Concentrate Average Price by Company (2021-2026)
  5. 3.5 Global Human Factor VIII Concentrate Company Ranking (2024-2026)
  6. 3.6 Global Human Factor VIII Concentrate Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Factor VIII Concentrate Company Product Type and Application
  8. 3.8 Global Human Factor VIII Concentrate Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Factor VIII Concentrate Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Factor VIII Concentrate Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Factor VIII Concentrate Market by Type
  1. 4.1 Human Factor VIII Concentrate Type Introduction
  2. 4.1.1 Blood Extraction
  3. 4.1.2 Recombine
  4. 4.2 Global Human Factor VIII Concentrate Sales Volume by Type
  5. 4.2.1 Global Human Factor VIII Concentrate Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Factor VIII Concentrate Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Human Factor VIII Concentrate Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Human Factor VIII Concentrate Sales Value by Type
  9. 4.3.1 Global Human Factor VIII Concentrate Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Factor VIII Concentrate Sales Value by Type (2021-2032)
  11. 4.3.3 Global Human Factor VIII Concentrate Sales Value Share by Type (2021-2032)
5 Human Factor VIII Concentrate Market by Application
  1. 5.1 Human Factor VIII Concentrate Application Introduction
  2. 5.1.1 Von Willebrand's Disease
  3. 5.1.2 Congenital Coagulation Factor VIII Deficiency
  4. 5.1.3 Acquired Factor VIII Deficiency
  5. 5.2 Global Human Factor VIII Concentrate Sales Volume by Application
  6. 5.2.1 Global Human Factor VIII Concentrate Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Factor VIII Concentrate Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Human Factor VIII Concentrate Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Human Factor VIII Concentrate Sales Value by Application
  10. 5.3.1 Global Human Factor VIII Concentrate Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Factor VIII Concentrate Sales Value by Application (2021-2032)
  12. 5.3.3 Global Human Factor VIII Concentrate Sales Value Share by Application (2021-2032)
6 Human Factor VIII Concentrate Regional Sales and Value Analysis
  1. 6.1 Global Human Factor VIII Concentrate Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Factor VIII Concentrate Sales by Region (2021-2032)
  3. 6.2.1 Global Human Factor VIII Concentrate Sales by Region: 2021-2026
  4. 6.2.2 Global Human Factor VIII Concentrate Sales by Region (2027-2032)
  5. 6.3 Global Human Factor VIII Concentrate Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Factor VIII Concentrate Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Factor VIII Concentrate Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Factor VIII Concentrate Sales Value by Region (2027-2032)
  9. 6.5 Global Human Factor VIII Concentrate Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Factor VIII Concentrate Sales Value (2021-2032)
  12. 6.6.2 North America Human Factor VIII Concentrate Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Factor VIII Concentrate Sales Value (2021-2032)
  15. 6.7.2 Europe Human Factor VIII Concentrate Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Factor VIII Concentrate Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Factor VIII Concentrate Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Factor VIII Concentrate Sales Value (2021-2032)
  21. 6.9.2 South America Human Factor VIII Concentrate Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Factor VIII Concentrate Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Factor VIII Concentrate Sales Value Share by Country, 2025 VS 2032
7 Human Factor VIII Concentrate Country-level Sales and Value Analysis
  1. 7.1 Global Human Factor VIII Concentrate Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Factor VIII Concentrate Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Factor VIII Concentrate Sales by Country (2021-2032)
  4. 7.3.1 Global Human Factor VIII Concentrate Sales by Country (2021-2026)
  5. 7.3.2 Global Human Factor VIII Concentrate Sales by Country (2027-2032)
  6. 7.4 Global Human Factor VIII Concentrate Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Factor VIII Concentrate Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Factor VIII Concentrate Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Factor VIII Concentrate Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Factor VIII Concentrate Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Factor VIII Concentrate Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shandong Taibang Biological Products
  2. 8.1.1 Shandong Taibang Biological Products Company Information
  3. 8.1.2 Shandong Taibang Biological Products Business Overview
  4. 8.1.3 Shandong Taibang Biological Products Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shandong Taibang Biological Products Human Factor VIII Concentrate Product Portfolio
  6. 8.1.5 Shandong Taibang Biological Products Recent Developments
  7. 8.2 Shanghai Xinxing Medicine
  8. 8.2.1 Shanghai Xinxing Medicine Company Information
  9. 8.2.2 Shanghai Xinxing Medicine Business Overview
  10. 8.2.3 Shanghai Xinxing Medicine Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Xinxing Medicine Human Factor VIII Concentrate Product Portfolio
  12. 8.2.5 Shanghai Xinxing Medicine Recent Developments
  13. 8.3 Shanghai Raas Corp
  14. 8.3.1 Shanghai Raas Corp Company Information
  15. 8.3.2 Shanghai Raas Corp Business Overview
  16. 8.3.3 Shanghai Raas Corp Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Raas Corp Human Factor VIII Concentrate Product Portfolio
  18. 8.3.5 Shanghai Raas Corp Recent Developments
  19. 8.4 Novo Nordisk A/S
  20. 8.4.1 Novo Nordisk A/S Company Information
  21. 8.4.2 Novo Nordisk A/S Business Overview
  22. 8.4.3 Novo Nordisk A/S Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk A/S Human Factor VIII Concentrate Product Portfolio
  24. 8.4.5 Novo Nordisk A/S Recent Developments
  25. 8.5 Grifols
  26. 8.5.1 Grifols Company Information
  27. 8.5.2 Grifols Business Overview
  28. 8.5.3 Grifols Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Grifols Human Factor VIII Concentrate Product Portfolio
  30. 8.5.5 Grifols Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Human Factor VIII Concentrate Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Hualan Biological
  38. 8.7.1 Hualan Biological Company Information
  39. 8.7.2 Hualan Biological Business Overview
  40. 8.7.3 Hualan Biological Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hualan Biological Human Factor VIII Concentrate Product Portfolio
  42. 8.7.5 Hualan Biological Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Human Factor VIII Concentrate Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 SinoCell Tech
  50. 8.9.1 SinoCell Tech Company Information
  51. 8.9.2 SinoCell Tech Business Overview
  52. 8.9.3 SinoCell Tech Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 SinoCell Tech Human Factor VIII Concentrate Product Portfolio
  54. 8.9.5 SinoCell Tech Recent Developments
  55. 8.10 Shire (Baxter)
  56. 8.10.1 Shire (Baxter) Company Information
  57. 8.10.2 Shire (Baxter) Business Overview
  58. 8.10.3 Shire (Baxter) Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shire (Baxter) Human Factor VIII Concentrate Product Portfolio
  60. 8.10.5 Shire (Baxter) Recent Developments
  61. 8.11 Octapharma
  62. 8.11.1 Octapharma Company Information
  63. 8.11.2 Octapharma Business Overview
  64. 8.11.3 Octapharma Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Octapharma Human Factor VIII Concentrate Product Portfolio
  66. 8.11.5 Octapharma Recent Developments
  67. 8.12 NovoNordisk
  68. 8.12.1 NovoNordisk Company Information
  69. 8.12.2 NovoNordisk Business Overview
  70. 8.12.3 NovoNordisk Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 NovoNordisk Human Factor VIII Concentrate Product Portfolio
  72. 8.12.5 NovoNordisk Recent Developments
  73. 8.13 GC Pharma
  74. 8.13.1 GC Pharma Company Information
  75. 8.13.2 GC Pharma Business Overview
  76. 8.13.3 GC Pharma Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 GC Pharma Human Factor VIII Concentrate Product Portfolio
  78. 8.13.5 GC Pharma Recent Developments
  79. 8.14 CSL
  80. 8.14.1 CSL Company Information
  81. 8.14.2 CSL Business Overview
  82. 8.14.3 CSL Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 CSL Human Factor VIII Concentrate Product Portfolio
  84. 8.14.5 CSL Recent Developments
  85. 8.15 Biogen
  86. 8.15.1 Biogen Company Information
  87. 8.15.2 Biogen Business Overview
  88. 8.15.3 Biogen Human Factor VIII Concentrate Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Biogen Human Factor VIII Concentrate Product Portfolio
  90. 8.15.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Factor VIII Concentrate Value Chain Analysis
  2. 9.1.1 Human Factor VIII Concentrate Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Factor VIII Concentrate Sales Mode & Process
  6. 9.2 Human Factor VIII Concentrate Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Factor VIII Concentrate Distributors
  9. 9.2.3 Human Factor VIII Concentrate Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst